Immunocore Advances Clinical Pipeline with Multiple Phase 3 Trials and New Drug Candidates
Key Insights
KIMMTRAK shows strong commercial performance with Q3 2024 revenues reaching $80.2 million, representing 28% growth year-over-year.
Company initiates multiple Phase 3 trials across melanoma indications, including PRISM-MEL-301 (search) and TEBE-AM (search) studies, with first data expected in 2026.
Immunocore (search) expands pipeline with first-in-class PIWIL1 (search)-targeted therapy and PRAME (search)-targeted IMC-P115C, demonstrating progress in novel cancer immunotherapy development.
Immunocore (search) Holdings plc is making significant strides in expanding its immunotherapy pipeline while achieving strong commercial growth with its flagship product KIMMTRAK. The company reported robust third-quarter 2024 financial results, with KIMMTRAK net revenues reaching $80.2 million, marking a 28% increase compared to the same period in 2023.
Expanding Melanoma Program
The company is actively pursuing an ambitious clinical development program in melanoma, with three Phase 3 trials currently underway. The PRISM-MEL-301 (search) and TEBE-AM (search) trials are investigating new applications in cutaneous melanoma (search), with initial data readouts anticipated in 2026. Additionally, the ATOM (search) trial, investigating tebentafusp as an adjuvant treatment for uveal melanoma (search), has begun patient enrollment.
The ATOM (search) trial represents a particularly significant milestone as it is currently the only active Phase 3 trial examining adjuvant treatment in uveal melanoma (search). This study aims to assess whether tebentafusp can reduce relapse risk in high-risk primary ocular melanoma patients.
Novel Pipeline Developments
Immunocore (search) has strengthened its innovative pipeline with the initiation of several first-in-human studies. The company recently announced the dosing of the first patient in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate targeting PRAME (search)-expressing tumors. This new drug candidate shares the same peptide target and CD3 effector specificity as brenetafusp but features an optimized half-life profile.
In another significant development, Immunocore (search) has launched a Phase 1/2 trial of IMC-R117C, marking the first immunotherapy program targeting PIWIL1 (search), a cancer-testis antigen overexpressed in various cancers, including colorectal cancer (search). The trial will evaluate the drug both as a monotherapy and in combination with standard treatments.
Commercial Expansion
The company continues to strengthen its market presence, recently securing a reimbursement agreement in England for KIMMTRAK for treating HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma (search). This agreement marks an important step in expanding access to this innovative treatment.
Corporate Development
In a strategic move to strengthen its leadership team, Immunocore (search) appointed Travis Coy as Executive Vice President, Chief Financial Officer, and Head of Corporate Development. Coy, who previously served as a Non-Executive Director, brings valuable experience to guide the company's financial strategy and corporate development initiatives.
Looking ahead, Immunocore (search) plans to present initial HIV Phase 1 MAD data in the first quarter of 2025, demonstrating its commitment to expanding its platform beyond oncology into infectious diseases. The company continues to advance its combination studies of brenetafusp in ovarian and lung cancer, while maintaining steady progress in dose escalation studies with its novel candidates.